Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
Thomas Marbury,1 Jerry Fox,2 Byron Kaelin,2 Leo Pavliv2 1Orlando Clinical Research Center, Inc., Orlando, FL, 2Department of Research and Development, Cumberland Pharmaceuticals, Inc., Nashville, TN, USA Purpose: Conivaptan is an intravenous dual V1A/V2 vasopressin antagonist approved for the treatm...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2017-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |